NLS Agreement

AstraZeneca and MedImmune announce the expansion of their clinical collaboration with Incyte Corporation. As part of the agreement, the companies will evaluate the efficacy and safety of epacadostat, Incyte’s investigational selective IDO1 enzyme inhibitor, in combination with AstraZeneca’s Imfinzi (durvalumab), a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone. The exclusive collaboration for the study population allows […]

Lipigon Pharmaceuticals has entered into a Target Validation Research Agreement with the German antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases. “We are very pleased for this exciting opportunity to work together with Secarna, bringing forward what we […]

Gyros Protein Technologies has signed a distribution agreement with Euro Diagnostica, which will give Gyros’ customers in Europe and North America direct access to the iLite assay ready cell lines. The iLite from Euro Diagnostica help customers overcome limitations of conventional cell-based assays and improve productivity. It is based upon a reporter gene assay format, modified […]

Promore Pharma announces that a manufacturing agreement has been entered with APL for the production of investigational medicinal product for its LL-37 Phase IIb trial in patients with hard-to-heal leg ulcers. The trial will be conducted in Europe with a planned start for patient enrolment in 2018. VLU constitutes the largest category of all chronic, […]

AstraZeneca has entered into an agreement with Aspen Global Incorporated, part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA,Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest. AstraZeneca entered into an agreement with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US. […]

Alligator Bioscience has signed a research collaboration agreement with Professor Ignacio Melero, MD, PhD, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain, to further investigate the biology of 4-1BB (CD137) as a target in cancer immunotherapy. Alligator has two pipeline programs targeting 4-1BB, the fully owned monospecific antibody ATOR-1017, and the bispecific antibody ALG.APV-527, […]